MIB Agents OsteoBites and osTEAo
By MIB Agents Osteosarcoma
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by MIB Agents Osteosarcoma
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 229
Description
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
| Episode | Date |
|---|---|
|
osTEAo: Let's Talk Childhood Cancer
|
Sep 17, 2026 |
|
A Phase 1b Study of Tegavivint, a TBL1 Inhibitor, with Gemcitabine in Patients with Relapsed or Refractory Osteosarcoma (TIGER)
|
Sep 14, 2026 |
|
CCDI Data Ecosystem in Action: Enabling Data-Driven Discovery
|
Sep 08, 2026 |
|
Functional Precision Medicine for Osteosarcoma
|
Aug 31, 2026 |
|
osTEAo: Same Summer, Different View
|
Aug 21, 2026 |
|
Dissecting and Targeting Metastatic Drivers in Osteosarcoma
|
Aug 14, 2026 |
|
Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis
|
Aug 10, 2026 |
|
Combinatorial immunotherapy to overcome cellular therapy resistance in osteosarcoma
|
Aug 03, 2026 |
|
Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade
|
Jul 24, 2026 |
|
osTEAo: Live from FACTOR '26!
|
Jul 16, 2026 |
|
osTEAo: Advocacy Doesn't End at Discharge
|
Jun 18, 2026 |
|
Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma
|
Jun 05, 2026 |
|
A Guide to FACTOR 2026 Scientific Panels
|
May 29, 2026 |
|
osTEAo - More Than Physical: The Mental Toll of Cancer
|
May 22, 2026 |
|
A Phase 1/2, Study to Evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in Patients with Relapsed/Refractory Osteosarcoma
|
May 15, 2026 |
|
Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma
|
May 08, 2026 |
|
Targeting Perioperative Myeloid Responses Through NOD/RIPK2 Modulation to Prevent Metastatic Progression in Osteosarcoma
|
Apr 24, 2026 |
|
osTEAo: The Sound of Strength
|
Apr 16, 2026 |
|
Zanzalintinib in Osteosarcoma: Balancing Disease Control and Quality of Life
|
Apr 10, 2026 |
|
Extracellular Matrix Degradation to Overcome Osteosarcoma Chemoresistance
|
Apr 03, 2026 |
|
Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma
|
Mar 27, 2026 |
|
Identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding
|
Mar 13, 2026 |
|
New insights into shared molecular and genomic features between humans and dogs with OS
|
Mar 06, 2026 |
|
Implementing personalized, adaptive therapies in osteosarcoma
|
Feb 27, 2026 |
|
osTEAo: The Sibling Side of Cancer
|
Feb 19, 2026 |
|
High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches
|
Feb 06, 2026 |
|
osTEAo: New Year, Same Cancer
|
Jan 26, 2026 |
|
Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma
|
Jan 16, 2026 |
|
Insights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting
|
Jan 08, 2026 |
|
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma
|
Dec 12, 2025 |
|
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution
|
Dec 05, 2025 |
|
osTEAo: Navigating Loss in the AYA Community
|
Nov 20, 2025 |
|
Synergy of ATM and PARP Inhibitors in Pediatric Osteosarcoma
|
Nov 10, 2025 |
|
Comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis
|
Oct 24, 2025 |
|
osTEAo - Spooky Sarcoma Stories
|
Oct 16, 2025 |
|
Insights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer
|
Oct 03, 2025 |
|
Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma
|
Sep 26, 2025 |
|
osTEAo - Turning Pain Into Purpose
|
Sep 18, 2025 |
|
Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes
|
Sep 12, 2025 |
|
Deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma
|
Aug 29, 2025 |
|
osTEAo: The Fault in Our Scars - Dating & Cancer
|
Aug 20, 2025 |
|
Clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group
|
Aug 01, 2025 |
|
Simultaneous targeting of CDK4/6 and BETs is independent of RB status in osteosarcoma
|
Jul 25, 2025 |
|
osTEAo: When Positivity Silences Pain
|
Jul 16, 2025 |
|
Old drugs, new tricks? A novel immunomodulatory approach to relapsed osteosarcoma therapy
|
Jul 11, 2025 |
|
Molecular subtyping of osteosarcoma, ecDNA and more
|
May 30, 2025 |
|
osTEAo: What to Expect When You're Not Expecting
|
May 15, 2025 |
|
A Guide to the FACTOR 2025 Scientific Panels with Matteo Trucco, MD
|
May 09, 2025 |
|
Autologous Cancer Vaccine with Checkpoint Inhibitor for Treatment of Canine Osteosarcoma
|
Apr 25, 2025 |
|
Stuck on the Sidelines: AYA Cancer & FOMO
|
Apr 17, 2025 |
|
Surgical Options and Advances in Osteosarcoma (La Cirugía de Salvamento de Extremidades)
|
Apr 10, 2025 |
|
Advocating for Cures: How You Can Support the Give Kids a Chance Act and Advance Pediatric Cancer Research
|
Apr 04, 2025 |
|
Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation
|
Mar 28, 2025 |
|
osTEAo: Accessibility Wins, Fails & WTF Moments
|
Mar 21, 2025 |
|
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children’s Oncology Group Bone Tumour Committee
|
Mar 17, 2025 |
|
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
|
Mar 07, 2025 |
|
Multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression
|
Feb 28, 2025 |
|
osTEAo: Paws and Reflect: How Pets Help Us Heal
|
Feb 14, 2025 |
|
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (PREMOST)
|
Feb 14, 2025 |
|
Minimally Invasive Metastasectomy in Canines (MIMIC)
|
Feb 07, 2025 |
|
Live-cell whole tissue models reveal sources of dynamic signaling heterogeneity and single cell drug response variation in the metastatic niche
|
Jan 24, 2025 |
|
osTEAo: Cancer Fatigue: How to Escape the Cancerverse
|
Jan 16, 2025 |
|
COG Blueprint for Research on Bone Tumors
|
Jan 14, 2025 |
|
Understanding Tumor Evolution in Osteosarcoma
|
Dec 13, 2024 |
|
Macrophage engineered vesicles to treat pediatric Osteosarcoma.
|
Dec 06, 2024 |
|
osTEAo: Hospital Holidays
|
Nov 21, 2024 |
|
Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma
|
Nov 07, 2024 |
|
Repurposing Drugs for Osteosarcoma
|
Oct 31, 2024 |
|
The ablative and immunomodulatory effects of histotripsy treatment in osteosarcoma
|
Oct 25, 2024 |
|
osTEAo: Spooky Sarcoma Stories
|
Oct 17, 2024 |
|
Molecular and cellular deconstruction of metastatic osteosarcoma
|
Sep 27, 2024 |
|
osTEAo: Back to School: Cancer + Curriculum
|
Sep 18, 2024 |
|
Fit for Filing Academic Clinical Trials: An Industry Perspective
|
Aug 30, 2024 |
|
Magnetic Resonance Guided (MRg) High Intensity Focused Ultrasound (HIFU) For Palliation of Canine Appendicular Osteosarcoma
|
Aug 23, 2024 |
|
osTEAo - Clear Scans…So Now What?
|
Aug 15, 2024 |
|
Clinical Utility of Functional Precision Medicine to Guide Treatments for Osteosarcoma Patients
|
Aug 08, 2024 |
|
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
|
Aug 02, 2024 |
|
A Multi-Institution Study in Combination with Relapsed or Refractory Pediatric Bone and Soft Tissue
|
Jul 26, 2024 |
|
osTEAo: The Sibling Situation
|
Jul 17, 2024 |
|
Genomes, Avatars and AI: The Future of Personalized Medicine
|
Jul 11, 2024 |
|
Exploring Novel Immunotherapies for Canine Osteosarcoma
|
May 31, 2024 |
|
A Guide to the FACTOR 2024 Scientific Panels with Matteo Trucco, MD
|
May 24, 2024 |
|
osTEAo: Long Term Side Effects from Treatment For Osteosarcoma and AYA Cancer
|
May 15, 2024 |
|
Creating a translational genomic framework for canine osteosarcoma: updates on the NCI DOG2 project
|
May 10, 2024 |
|
Positioning Poly-(ADP)-ribose polymerase inhibitors (PARPi) for the treatment of Osteosarcoma
|
May 03, 2024 |
|
TGF-beta inhibition as a novel therapeutic option in Osteosarcoma
|
Apr 25, 2024 |
|
Out on a Limb - Travel Tips for AYA Cancer Patients
|
Apr 17, 2024 |
|
Phase 1 Study of Cabozantinib in Combination with Topotecan-Cyclophosphamide for Patients with Relapsed or Refractory Ewing Sarcoma or Osteosarcoma
|
Apr 11, 2024 |
|
Targeting Urea Cycle Dysfunction to Prevent and Treat Osteosarcoma Metastasis
|
Apr 05, 2024 |
|
osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma
|
Mar 21, 2024 |
|
Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research
|
Mar 14, 2024 |
|
Patient perspectives on participating in research and clinical trials
|
Mar 08, 2024 |
|
Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery
|
Mar 01, 2024 |
|
Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study
|
Feb 23, 2024 |
|
Managing Stress in AYA Cancer Patients
|
Feb 15, 2024 |
|
Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma
|
Feb 09, 2024 |
|
TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma
|
Jan 26, 2024 |
|
osTEAo: Making friends after a cancer diagnosis
|
Jan 18, 2024 |
|
Interventions to promote physical function during and after treatment for osteosarcoma
|
Jan 11, 2024 |
|
The Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (CAUSAL) study
|
Dec 15, 2023 |
|
Developing a Multiscale Transcriptional Atlas of Sarcoma
|
Dec 08, 2023 |
|
Immunological Mechanisms of Cancer Defense
|
Dec 01, 2023 |
|
osTEAo: Long Term Osteosarcoma Survivors: Where They Were and Where They Are Now
|
Nov 16, 2023 |
|
Cabozantinib as a Maintenance Therapy to Prevent Recurrence of High-Risk Pediatric Solid Tumors
|
Oct 27, 2023 |
|
osTEAo - Coping with Cancer through Music
|
Oct 19, 2023 |
|
OsteoBites Preguntas & Respuestas con Nino Rainusso, MD
|
Oct 13, 2023 |
|
TCF-001 TRACK (Target Rare Cancer Knowledge): A Clinical Trial Studying Precision Medicine in Rare Cancers
|
Oct 06, 2023 |
|
Repurposing Disulfiram to Overcome Chemotherapy Resistance in Relapsed Sarcomas
|
Sep 29, 2023 |
|
osTEAo Tea Spill: AYA Cancer Gab Sesh
|
Sep 20, 2023 |
|
Addressing the Unmet Scientific Challenges in Osteosarcoma Treatment through Innovative Engineering Techniques
|
Sep 15, 2023 |
|
Implementing Multi-Targeted Tyrosine Kinase Inhibitors in Combination with Chemotherapy for Osteosarcoma
|
Sep 01, 2023 |
|
Immune Therapies in EGFR-Expressing Cancers
|
Aug 25, 2023 |
|
OsTEAo - An Honest Q&A with Osteosarcoma AYA Patients, Survivors, and Siblings
|
Aug 17, 2023 |
|
Treatment of Osteosarcoma Using Smart Targeted Drug Delivery Nanoplatforms
|
Aug 11, 2023 |
|
MIB Agents and SARC: A Case Study in Collaboration
|
Aug 04, 2023 |
|
OSI Funded Work
|
Jul 28, 2023 |
|
OsTEAo - Survivor's Guilt and Grief with grief coach Lori Krause
|
Jul 20, 2023 |
|
Pretargeted Approach to Delivery of Radiopharmaceutical Therapy for Bone Cancer - a Click Chemistry Study in Canines with Osteosarcoma
|
Jul 14, 2023 |
|
osTEAo - Coping with Humor: A Review of Cancer Memes
|
Jun 15, 2023 |
|
The Importance of Patient-Powered Osteosarcoma Research: Count Me In
|
Jun 09, 2023 |
|
Osteosarcoma Organoid Models: The Potential and Limitations of Personalized Avatars
|
Jun 02, 2023 |
|
Reprogramming NK Cells Within the Tumor Microenvironment of Osteosarcoma Lung Metastases
|
May 26, 2023 |
|
osTEAo- Returning to Yourself: Confidence and Identity as an AYA Cancer Patient
|
May 18, 2023 |
|
OSI Connect: Osteosarcoma Answers and Assistance
|
May 12, 2023 |
|
Open Clinical Trial: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
|
May 09, 2023 |
|
SCF-Skp2 Protein Complex as a Therapy for Osteosarcoma by Blocking the Mutational Effects of Rb and p53
|
Apr 28, 2023 |
|
osTEAo - Navigating Scanxiety
|
Apr 20, 2023 |
|
Cold Atmospheric Plasma: A New Therapeutical Option for Osteosarcoma?
|
Apr 14, 2023 |
|
UHRF1 Overexpression Promotes Osteosarcoma Metastasis through Altered Exosome Production and AMPK/SEMA3E Suppression
|
Mar 31, 2023 |
|
Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiosurgery (SRS) for Sarcoma
|
Mar 24, 2023 |
|
osTEAo - Navigating Campus: Limb-Salvage and Amputation Patient Perspectives
|
Mar 16, 2023 |
|
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
|
Mar 10, 2023 |
|
SarcoSIGHT- A Randomised Controlled Trial of Fluorescence Guided Sarcoma Surgery versus Standard Care
|
Mar 03, 2023 |
|
Virtual Surgical Planning and 3D Printing in Pediatric Musculoskeletal Oncological Resections
|
Feb 17, 2023 |
|
Two Epigenetically Distinct Cellular States in Osteo are Regulated by a State-Specific Set of Transcription Factors Driving Differential Drug Response
|
Jan 27, 2023 |
|
Clinical Trial: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
|
Jan 13, 2023 |
|
Cell Based Therapies for Osteosarcoma
|
Dec 09, 2022 |
|
osTEAo Q&A with Dr. Kurt Weiss - What questions do you have about Osteosarcoma but are afraid to ask?
|
Nov 17, 2022 |
|
Interventional Radiology/HIFU Perspectives for Osteosarcoma
|
Nov 11, 2022 |
|
Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma
|
Nov 04, 2022 |
|
Updates from Clinical Sequencing of 2,138 Bone and Soft Tissue Sarcomas
|
Oct 28, 2022 |
|
osTEAo Presents Halloween Spooky Stories
|
Oct 20, 2022 |
|
How Osteosarcoma Evolves from Diagnosis to Relapse
|
Oct 14, 2022 |
|
Transforming the Way Researchers Share Data: Lessons from the Pediatric Cancer Data Commons
|
Oct 07, 2022 |
|
osTEAo - Dating & Intimacy with Lauren Broschak, MSW, LCSW, OSW-C
|
Sep 22, 2022 |
|
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma
|
Sep 16, 2022 |
|
Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma
|
Sep 09, 2022 |
|
Inhaled Recombinant Human IL-15 in Dogs with Naturally Occurring Pulmonary Metastases from Osteosarcoma or Melanoma: a Phase 1 Study
|
Sep 02, 2022 |
|
Outsmarting OS 2021 Funded Research Update: Exploring Aldehyde Dehydrogenase and Androgen Receptor Actions to OutSmart Osteosarcoma Metastases
|
Aug 26, 2022 |
|
Back to School: OsteoWarrior and OsteoSibling Perspectives
|
Aug 18, 2022 |
|
Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma
|
Aug 12, 2022 |
|
Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma
|
Aug 05, 2022 |
|
COG Project: Every Child - Episode Sponsored by Osteosarcoma Institute
|
Jul 30, 2022 |
|
Body Image for AYAs with Cancer with Dr. Lori Weiner
|
Jul 21, 2022 |
|
Unanswered Clinical Questions in Sarcoma: Opportunities to Move from Bedside to Bench - Episode Sponsored by Osteosarcoma Institute
|
Jul 15, 2022 |
|
Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer - Episode Sponsored by Osteosarcoma Institute
|
Jul 10, 2022 |
|
Navigating Pediatric Cancer Clinical Trials
|
Jun 20, 2022 |
|
Update on OSI funded phase 2 Trial of Olaparib + Ceralasertib in Recurrent Osteosarcoma
|
Jun 10, 2022 |
|
Limb Salvage Surgery for OS: Patient & Surgeon Perspectives sponsored by the Osteosarcoma Institute
|
May 27, 2022 |
|
"Armored" CAR T cells for Osteosarcoma sponsored by BTG Specialty Pharmaceuticals
|
May 20, 2022 |
|
Immunotherapy for Osteosarcoma - Where Do We Go From Here? Sponsored by BTG Specialty Pharmaceuticals
|
May 13, 2022 |
|
The Osteosarcoma Project sponsored by BTG Specialty Pharmaceuticals
|
May 06, 2022 |
|
osTEAo Debut
|
Apr 29, 2022 |
|
Update on Clinical Trial Development Targeting Tumor Microenvironment in Refractory and Metastatic Osteosarcoma
|
Apr 22, 2022 |
|
Exploring the Use of a Predictive Tool for Methotrexate Clearance sponsored by BTG Specialty Pharmaceuticals
|
Apr 15, 2022 |
|
A Phase 1/2 Study of ZN-c3 Plus Gemcitabine in Relapsed or Refractory Osteosarcoma
|
Apr 15, 2022 |
|
MYC Amplification as a Prognostic Biomarker in Osteosarcoma Sponsored by BTG Speciality Pharmaceuticals
|
Apr 01, 2022 |
|
Compassionate Use of Investigational Drugs: A Strategy to Access Unapproved Therapies for Pediatric Oncology Patients Presented by BTG Speciality Pharmaceuticals
|
Mar 25, 2022 |
|
The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) International Randomized Controlled Trial Sponsored by BTG Specialty Pharmaceuticals
|
Mar 18, 2022 |
|
Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals
|
Mar 11, 2022 |
|
Truths & Myths of Nutrition in Cancer sponsored by BTG Specialty Pharmaceuticals
|
Mar 04, 2022 |
|
Amputation for OS; Patient & Surgeon Perspectives sponsored by BTG Speciality Pharmaceuticals
|
Feb 25, 2022 |
|
Surgical Management of Pulmonary Metastases in People with Osteosarcoma - COG Trial
|
Feb 18, 2022 |
|
Human Trial for OST-HER2
|
Feb 11, 2022 |
|
Osteosarcoma Q&A with Dr. Peter Anderson and OsteoWarriors
|
Feb 04, 2022 |
|
Osteobites: Back to Activity, Rotationplasty
|
Dec 17, 2021 |
|
OsteoBites: Clinical Trials for Relapsed or Refractory Osteosarcoma - The OLIE Study and Beyond!
|
Nov 19, 2021 |
|
Encore, Testing & Research Directory
|
Nov 12, 2021 |
|
Real Talk: What it's really like and how WE feel about Osteosarcoma.
|
Nov 08, 2021 |
|
Planning for Dignity and What Matters Most to You
|
Oct 22, 2021 |
|
Let's Talk Fertility and Osteosarcoma
|
Sep 24, 2021 |
|
How "Hydroxychloroquine and "self-eating" works with Osteosarcoma.
|
Sep 17, 2021 |
|
Osteosarcoma Update from Dr. Huang - 2019 OutSmarting Osteosarcoma recipient
|
Sep 12, 2021 |
|
OsteoBites Welcomes Junior Board Members to discuss "Four OsteoWarriors' Perspectives".
|
Jul 30, 2021 |
|
OsteoBites welcomes Dr. Moyez Jiwa to discuss "The Art of Doctoring"
|
Jul 23, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 18: Richard Gorlick, MD & Yifei Wang, MD “Antibody Drug Conjugates for Osteosarcoma”
|
Jun 24, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 17: Lara Davis, MD, OHSU Knight Cancer Institute “New Osteosarcoma Clinical Trials”
|
Jun 17, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 16: Julie Lanford, MPH, RD, CSO, LDN on “Nutrition & Cancer; Truths & Myths”
|
Jun 10, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 15: Katie Greenzang, MD, EdM Dana-Farber CI & Harvard Med School “What’s Next? Survivorship"
|
May 20, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 14: Lillian Guenther, MD Dana-Farber CI & Harvard Med School “CRISPR Screening to Identify Novel Genomic Targets"
|
May 13, 2021 |
|
Osteosarcoma OsteoBites S2 E13: Scott Sauer, PhD on “Preventing Osteosarcoma Lethal Recurrence by Targeting Disseminated Tumor Cells”
|
May 06, 2021 |
|
Osteosarcoma OsteoBites S2 Ep12: Dan Prince, MD, MPH on “Regenerative Surgery for Bone Sarcomas”
|
Apr 29, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 11: Ines Lohse, PhD on “Drug Sensitivity Testing for the Treatment Stratification of Cancer Patients”
|
Apr 22, 2021 |
|
Osteosarcoma OsteoBites S2 Ep 10: Sumit Gupta, MD, PhD, FRCPC “Long Term Mental Health Outcomes in Adolescents and Young Adults with Cancer”
|
Apr 15, 2021 |
|
MIB Agents OsteoBites S2 Ep 9: Jane Yanagawa, MD, “Osteosarcoma Lung Metastases”
|
Apr 08, 2021 |
|
OsteoBites S2 Ep 8: Chand Khanna DVM, PhD, “A Comparative Approach To Metastasis: Biology and Therapy”
|
Apr 01, 2021 |
|
OsteoBites S2 Ep7: Corrie Painter, PhD “The Osteosarcoma Project, Patient-Partnered Research Update”
|
Mar 05, 2021 |
|
OsteoBites S2 Ep6: Brian Van Tine, MD, PhD on “Osteosarcoma Tumor Metabolism”
|
Feb 11, 2021 |
|
OsteoBites S2 Ep5: Robbie Majzner, MD on “Unleashing the Pediatric Immune System Against Osteosarcoma and Other Solid Tumors”
|
Feb 04, 2021 |
|
OsteoBites S3 Ep4: Lor Randall, MD, "Sarcomatology: A Trans-Disciplinary Approach"
|
Jan 29, 2021 |
|
OsteoBites S2 Ep3: Pete Anderson, MD, PhD "Understanding Lab, Path and Scan Reports and Other Questions Answered"
|
Jan 21, 2021 |
|
OsteoBites S2 Ep2: Alejandro Sweet Cordero, MD "Genome-Informed Targeted Therapies for Osteosarcoma"
|
Jan 14, 2021 |
|
OsteoBites S2 Ep1: Erin Murphy, Associate Professor, Radiation Oncology at Cleveland Clinic: Radiosurgery and SBRT for Sarcoma”
|
Jan 08, 2021 |
|
OsteoBites S1 Ep28: Ryan Roberts, MD, PhD. “Dear Lungs, Stop enabling this cancer: Targeting interactions that facilitate osteosarcoma metastasis.”
|
Nov 21, 2020 |
|
OsteoBites S1 Ep27: Brian Crompton, MD, “New Genomic Approaches to Understanding Osteosarcoma”
|
Nov 15, 2020 |
|
OsteoBites S1 Ep25: Sulagna Banerjee, PhD, “Modeling Osteosarcoma in Mice”
|
Oct 16, 2020 |
|
OsteoBites S1 Ep24: Andy Woods & Charles Keller, MD: "Legacy Autopsy”
|
Sep 25, 2020 |
|
Lauren: Osteosarcoma Survivor, Sibling of OsteoAngel and MIB Jr. Board Member
|
Sep 21, 2020 |
|
OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma ”
|
Sep 18, 2020 |
|
OsteoBites S1 Ep22: Reed: "Moffitt Osteosarcoma Research Approach”
|
Sep 10, 2020 |
|
OsteoBites S1 Ep21: Kurt Weiss, MD, A Day In the Life of a Musculoskeletal Oncologist
|
Aug 28, 2020 |
|
OsteoBites S1 Ep20: Correlative Science Leading to Active and Emerging Clinical Trials for #Osteosarcoma
|
Aug 21, 2020 |
|
OsteoBites S1 Ep19: Modeling & Targeting MYC-Driven Osteosarcoma
|
Aug 14, 2020 |
|
OsteoBites S1 Ep18: Coping Through Cancer: Tips for Parents & Caregivers
|
Aug 10, 2020 |
|
OsteoBites S1 Ep17: The #Osteosarcoma Patient Decision Aid for Surgical Options in the Lower Extremity
|
Jul 30, 2020 |
|
OsteoBites S1 Ep16: Peter Anderson, MD, PhD on Making It Better for OS Patients
|
Jul 23, 2020 |
|
OsteoBites S1 Ep15: Survivorship Care Planning with David Poplack, MD and Ellen Shohet, RN
|
Jul 17, 2020 |
|
OsteoBites S1 Ep14 Katie Janeway, MD, NEW Osteosarcoma Clinical Trial
|
Jul 10, 2020 |
|
OsteoBites S1 Ep12: John Healey, MD, Precision Surgery for Osteosarcoma
|
Jul 02, 2020 |
|
OsteoBites S1 Ep11: Alanna Church, MD and Christina Ip-Toma, MIB Testing & Research Directory
|
Jun 19, 2020 |
|
OsteoBites S1 Ep10: Simon Holland and Elly App
|
Jun 12, 2020 |
|
OsteoBites S1 Ep9: Amputee Coalition
|
Jun 04, 2020 |
|
OsteoBites S1 Ep8: Osteosarcoma Research, Joshua Schiffman, MD
|
May 28, 2020 |
|
OsteoBites S1 Ep7: Osteosarcoma Research, Matteo Trucco, MD
|
May 23, 2020 |
|
OsteoBites S1 Ep6: Osteosarcoma Research, J. Andrew Livingston, MD
|
May 14, 2020 |
|
OsteoBites S1 Ep5: Osteosarcoma Research, Alex Huang, MD, PhD of UH Rainbow Babies & Children's & CWRU
|
May 08, 2020 |
|
OsteoBites S1 EP2: Osteosarcoma Q&A with Matteo Trucco, MD of Cleveland Clinic
|
May 06, 2020 |
|
OsteoBites S1 Ep4: Upfront Surgery for Osteosarcoma, David Loeb, MD, PhD & Matteo Trucco, MD
|
May 02, 2020 |
|
OsteoBites: S1, EP3 Osteosarcoma Institute with Lee Helman, MD & Joyce Schaffer, RN
|
Apr 27, 2020 |